Agenus Inc. Stock price

Equities

AGEN

US00847G7051

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
0.58 USD +4.24% Intraday chart for Agenus Inc. +3.17% -29.94%
Sales 2024 * 279M Sales 2025 * 199M Capitalization 243M
Net income 2024 * -162M Net income 2025 * -285M EV / Sales 2024 * 0.87 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 1.22 x
P/E ratio 2024 *
-1.42 x
P/E ratio 2025 *
-0.84 x
Employees 389
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.81%
More Fundamentals * Assessed data
Dynamic Chart
1 day+4.24%
1 week+3.17%
Current month-13.43%
1 month-22.79%
3 months-28.40%
6 months-48.21%
Current year-29.94%
More quotes
1 week
0.53
Extreme 0.532
0.58
1 month
0.49
Extreme 0.485
0.74
Current year
0.49
Extreme 0.485
0.95
1 year
0.49
Extreme 0.485
2.13
3 years
0.49
Extreme 0.485
6.79
5 years
0.49
Extreme 0.485
6.79
10 years
0.49
Extreme 0.485
10.16
More quotes
Managers TitleAgeSince
Chief Executive Officer 71 94-03-30
Director of Finance/CFO 58 95-12-31
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Chief Executive Officer 71 94-03-30
Director/Board Member 66 16-05-16
Director/Board Member 71 20-10-07
More insiders
Date Price Change Volume
24-03-28 0.58 +4.24% 5,513,174
24-03-27 0.5564 +3.73% 3,681,348
24-03-26 0.5364 -3.94% 5,159,745
24-03-25 0.5584 +2.25% 5,366,077
24-03-22 0.5461 -2.86% 5,118,735

Delayed Quote Nasdaq, March 28, 2024 at 04:00 pm EDT

More quotes
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is I-O, and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody (AGEN1811)) and balstilimab (a programmed death receptor-1 (PD-1) blocking antibody). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.58 USD
Average target price
5.5 USD
Spread / Average Target
+848.28%
Consensus
  1. Stock
  2. Equities
  3. Stock Agenus Inc. - Nasdaq